Alice T. Shaw
0000-0001-6337-1093
Publication & Citation Trends
Publications
0 total
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.
Cited by 6
Semantic Scholar
Abstract 3468: Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer
Cited by 0
Semantic Scholar
Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer. OA
Cited by 26
Semantic Scholar
Therapy-induced APOBEC3A drives evolution of persistent cancer cells OA
Cited by 107
Semantic Scholar
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer. OA
Cited by 2
Semantic Scholar
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations. OA
Cited by 35
Semantic Scholar
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer OA
Cited by 137
Semantic Scholar
ALK-positive lung cancer: a moving target OA
Cited by 143
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(547)
Lung Cancer Research Studies
(260)
Cancer Genomics and Diagnostics
(143)
Colorectal Cancer Treatments and Studies
(139)
Cancer therapeutics and mechanisms
(109)
Affiliations
Université Paris-Sud
Broad Institute
Genomics Institute of the Novartis Research Foundation
Brigham and Women's Hospital
Novartis (Switzerland)